UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 6, 2007
NUVASIVE, INC.
(Exact name of registrant as specified in its charter)
000-50744
( Commission File Number )
| |
|
|
|
| |
Delaware
|
|
33-0768598 |
| |
(State or other jurisdiction of
|
|
(I.R.S. Employer Identification No.) |
| |
incorporation) |
|
|
4545 Towne Centre Court, San Diego, California 92121
(Address of principal executive offices, with zip code)
(858) 909-1800
(Registrant’s telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Item 5.02 Departures of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers; Compensatory Arrangements of Certain Officers
On June 6, 2007, the Board of Directors (the “Board”) of NuVasive, Inc. (the “Company”), upon
recommendation by its Nominating and Corporate Governance Committee, elected Ms. Eileen M. More to
serve as a Director of the Company, effective June 6, 2007. Ms. More’s term as a member of the
Board of Directors is set to expire at the Company’s Annual Meeting of Stockholders in 2009. There
is no arrangement or understanding between Ms. More and any other person pursuant to which Ms. More
was selected as a director of the Company. Ms. More does not have any direct or indirect material
interest in any existing or proposed transaction to which the Company is or may become a party. The
addition of Ms. More brings the Company’s Board to eight members.
During Ms. More’s distinguished career, she has worked primarily in venture capital and as an
investment analyst. Until 2002, Ms. More was a General Partner at Oak Investments, one of the
largest venture capital funds in the United States, which she joined in 1978. Ms. More founded
Oak’s healthcare investment practice, and was also an active investor in the information technology
and retail sectors, with early stage investments in dozens of successful healthcare and technology
companies. Ms. More’s focus has been on identifying promising companies and management teams, and
building companies. Her investments include leadership roles with Genzyme Corporation, Alexion
Pharmaceuticals, OraPharma, Inc., Osteotech, Inc. and Compaq Computer.
Ms More
retired from Oak in 2002, but continues to serve on
several boards. Ms. More is Chairman Emeritus of the Connecticut Venture Group and a Board member
of the University of Connecticut Research and Development Corporation.
For her service on the Board and each committee, Ms. More will receive a cash retainer pursuant to
the Company’s standard compensation practices. Ms. More was also awarded, on the date of her
appointment, an option to purchase up to 42,000 shares of the Company’s common stock under the
Company’s 2004 Equity Incentive Plan (the “2004 Plan”). The 2004 Plan also provides for an
automatic annual grant of an option to purchase 6,000 shares of the Company’s common stock in
connection with each future annual meeting of stockholders.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
| |
|
|
Exhibit 99.1
|
|
Press release issued by NuVasive, Inc. on June 7, 2007. |
-2-